Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
10-11 February 2020

22nd BIO CEO & Investor Conference

New York Marriott Marquis

NY

United States

4-5 February 2020

6th Annual LSX World Congress 2020

133 Houndsditch, Liverpool St

London

United Kingdom

28 January 2020

BioMed Event

Les Salons Hoche, 9 Avenue Hoche

Paris

France

27 January 2020

ORYZON to present at upcoming international conferences

8 January 2020

ORYZON to present at the 3rd Neuroscience Innovation Forum in San Francisco

9 December 2019

ORYZON presents new efficacy data from its Phase II trial ALICE investigating iadademstat in AML

2 December 2019

ORYZON to present at upcoming international conferences

11 November 2019

ORYZON to present at upcoming international conferences

25 October 2019

ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter, 2019

21 October 2019

ORYZON updates on new activities

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Current page 35
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel